Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Jonathan H. Schatz; Hans-Guido Wendel (Profiled Author: Hans Wendel)
Cell Cycle. 2011;10(22):3830-3833.Abstract
"Shoot the driver" is the paradigm of targeted cancer therapy. However, resistance to targeted inhibitors of signaling pathways is a major problem. In part the redundancy of signaling networks can bypass targeted inhibitors and thereby reduce their biological effect. In this case the driver turns out to be one of several potential messengers and is easily replaced. Cocktails of multiple targeted inhibitors are an obvious solution. This is limited, however, by the lack of potent inhibitors and may also produce increased toxicity. Therefore we explored the direct blockade of a key biological activity downstream from multiple converging oncogenic signals. Specifically, several oncogenic signaling pathways including AKT, MAPK and PIM kinase signals converge on the activation of capdependent translation. In cancer cells, aberrant activation of cap-dependent translation favors the increased expression of short-lived oncoproteins like c-MYC, MCL1, CYCLIN D1 and the PIM kinases. Intriguingly, cancer cells are especially sensitive to even temporary reductions in these proteins. We will discuss our findings concerning translational inhibitor therapy in cancer. © 2011 Landes Bioscience.
PMID: 22064518 PMCID: PMC3266113
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Jonathan H. Schatz; Elisa Oricchio; Andrew L. Wolfe; Man Jiang; Irina Linkov; Jocelyn Maragulia; Weiji Shi; Zhigang Zhang; Vinagolu K. Rajasekhar; Nen C. Pagano; et al.Journal of Experimental Medicine. 2011;208(9):1799-1807.
Daniela Buglio; Sangeetha Palakurthi; Kate Byth; Francisco Vega; Dorin Toader; Jamal Saeh; Sattva S. Neelapu; Anas YounesBlood. 2012;120(2):347-355.
Neal I. Lindeman; Philip T. Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J. Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; et al.
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the college of American pathologists, international association for the study of lung cancer, and association for molecular pathologyJournal of Thoracic Oncology. 2013.
Appears in this Document